Does Lowering LDL-C to Ultra-Low Levels Provide Additional Benefit?
The researchers observed these endpoints according to degree of LDL cholesterol reduction after 1 month of treatment.
ESC 2017
CABG vs. PCI in Patients with Type 1 Diabetes and Multivessel Disease
Compared with CABG, PCI was associated with similar risks of all-cause mortality, and with elevated risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization.
Apixaban Compared to Standard Care in NVAF Patients Undergoing Cardioversion
This is an investigational use for Eliquis.
Does Oxygen Therapy Reduce Mortality in Suspected Acute MI?
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
Statins and Breast Cancer: What’s the Link?
Researchers concluded that the use of statins is the likely cause of this diagnosis appearing to be beneficial against breast cancer development and subsequent death.
Is There an Ideal BP Target? Analysis Says It May Vary
After adjusting for age and gender, patients randomized to the aggressive treatment arm demonstrated triple the risk of mortality from any cause vs. patients who received less intense treatment (4.9% vs. 1.7%, hazard ratio [HR] 3.12, 95% CI: 1.00-9.69; P=0.012).
Spironolactone and Amiloride Effective in Drug-Resistant Hypertension
Several sub-studies investigated the superior efficacy of spironolactone in RHTN and whether there was potential benefit with amiloride in the same population.
Coffee Consumption Linked to Reduced Mortality Risk
Four cups a day could reduce risk by 64 percent, researchers say
Clinical Benefit of Lowering LDL-C May Depend on How It Is Lowered
Change in apoB levels may be better predictor of clinical response than LDL-C, HDL-C levels
For STEMI Patients, Mineralocorticoid Antagonists May Up Survival
MRAs such as spironolactone and eplerenone are “still underused in routine clinical practice” but can be effective in countering the harms of high aldosterone levels, explained study author Professor Farzin Beygui, MD, PhD.
